Jeremiah D. Momper, Pharm.D., Ph.D.
Professor of Clinical Pharmacy
Skaggs School of Pharmacy and Pharmaceutical Sciences
Dr. Momper’s research program integrates clinical pharmacology, quantitative pharmacometrics, and advanced bioanalytical chemistry to advance drug dosing strategies and guide regulatory decision-making.
His work focuses on therapeutic optimization and individualization in complex patient populations, particularly pregnant women, neonates, and children, including studies of maternal–infant pharmacology and drug exposure through breastfeeding. He has served as protocol pharmacologist on numerous multicenter clinical trials within the International Maternal Pediatric Adolescent AIDS Clinical Trials Network (IMPAACT), where his research has informed clinical practice guidelines and drug labeling for antiretroviral and anti-infective therapies used during pregnancy and early life.
Dr. Momper also directs the Cannabis Reference Laboratory within the Center for Medicinal Cannabis Research (CMCR) at UC San Diego, which serves as a reference laboratory for the California Department of Cannabis Control. The laboratory develops and applies analytical methods to characterize cannabis products in support of regulatory oversight aimed at protecting public health and public safety in California’s regulated cannabis market.
Education: Pharm.D. (2006) University of Pittsburgh; Ph.D. in Pharmaceutical Sciences (2011) University of Pittsburgh; Commissioner’s Fellow (2011-2013) Office of Clinical Pharmacology, Center for Drug Evaluation and Research, U.S. Food and Drug Administration
- Course Chair, Clinical Pharmacokinetics (SPPS 226)
- Course Chair, Regulatory Submissions and Strategy (DDPM 203)
- Biopharmaceutics (SPPS 224)
- Dosage Forms and Delivery Systems (SPPS 225)
- Renal System I (SOMC 225)
- Principles of Pharmaceutical Sciences and Drug Development (SPPS 263B)
- Circadian Rhythms and Health (NEU 233)
- Characterized the population pharmacokinetics and dosing requirements of fluconazole for prophylaxis of invasive candidiasis in premature infants
- Described the pharmacokinetics of multiple antiretroviral drugs in pregnant women and their infants
- Developed a quantitative model of organic anion transporter (OAT)-mediated tubular secretion capacity across the pediatric age continuum
- Momper JD, et al. (2016) Population Pharmacokinetics of Fluconazole in Premature Infants with Birth Weights Less than 750 Grams. Antimicrob Agents Chemother, 60:5539-45.
- Momper JD, et al. (2018) Elvitegravir/Cobicistat Pharmacokinetics in Pregnant and Postpartum Women with HIV. AIDS. 32(17):2507-2516.
- Momper JD, et al. (2019) Dynamics of Organic Anion Transporter-Mediated Tubular Secretion During Postnatal Human Kidney Development and Maturation. Clin J Am Soc Nephrol. 5;14(4):540-548.
- Momper JD, et al. (2019) Determination of Benznidazole in Human Dried Blood Spots by Liquid Chromatography Mass Spectrometry to Monitor Adherence to Trypanosoma cruzi Infection Treatment in Infants and Children. Am J Trop Med Hyg. 101(1):116-122.
- Momper JD, et al. (2020) Extrapolation of Adult Efficacy to Pediatric Patients With Chemotherapy-Induced Nausea and Vomiting. J Clin Pharmacol. 60(6):775-784.
- Nigam SK, et al. (2020) The Systems Biology of Drug Metabolizing Enzymes and Transporters: Relevance to Quantitative Systems Pharmacology. Clin Pharmacol Ther. 108(1):40-53.
- Alloway RR, et al. (2020) Chronopharmacokinetics and Food-Effects of Single-Dose LCP-tacrolimus in Healthy Volunteers. Ther Drug Monit. 42(5):679-685
- Momper JD, et al. (2021) Ethical Considerations for Pediatric Placebo-Controlled Trials: FDA Outcomes and Perspectives. Ther Innov Regul Sci. 55(2):282-303
- Piscitelli J, et al. (2022) Optimizing Dolutegravir Initiation in Neonates Using Population Pharmacokinetic Modeling and Simulation. J Acquir Immune Defic Syndr. 89(1):108-114
- Liyanage M, et al. (2023). Variable Delta-9-Tetrahydrocannabinol Pharmacokinetics and Pharmacodynamics After Cannabis Smoking in Regular Users. Ther Drug Monit. 1;45(5):689-696.
- Brooks KM, et al. (2024). Pharmacokinetics and Safety of Remdesivir in Pregnant and Nonpregnant Women With COVID-19: Results From IMPAACT 2032. J Infect Dis. 16;230(4):878-888.
- Powis KM, et al. (2025). Pharmacokinetics and Safety of Bictegravir in Pregnant and Postpartum Persons With HIV and Their Infants. J Acquir Immune Defic Syndr. 98(3):300-307.
- Model-informed pediatric drug development
- Clinical pharmacology protocol design and data analysis
- Pre-clinical and clinical pharmacokinetic studies
- Bioanalytical chemistry for the quantitative determination of drugs and metabolites in biological matrices